Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:DNLI NASDAQ:NAMS NASDAQ:ORIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$24.84+0.0%$23.23$19.69▼$28.35$4.25B0.81.73 million shs1.05 million shsDNLIDenali Therapeutics$23.11-1.3%$22.61$12.58▼$27.30$3.67B0.961.94 million shs1.16 million shsNAMSNewAmsterdam Pharma$29.64-3.0%$32.80$21.14▼$42.21$3.47B0.08945,305 shs1.09 million shsORICOric Pharmaceuticals$12.10+11.1%$9.39$7.23▼$14.93$1.25B1.021.57 million shs3.61 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%-2.97%+4.72%+13.11%+6.75%DNLIDenali Therapeutics0.00%-0.77%-6.55%+16.31%+59.71%NAMSNewAmsterdam Pharma0.00%-6.44%-6.59%-0.27%+23.60%ORICOric Pharmaceuticals0.00%+12.77%+27.91%+18.16%+2.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$24.84+0.0%$23.23$19.69▼$28.35$4.25B0.81.73 million shs1.05 million shsDNLIDenali Therapeutics$23.11-1.3%$22.61$12.58▼$27.30$3.67B0.961.94 million shs1.16 million shsNAMSNewAmsterdam Pharma$29.64-3.0%$32.80$21.14▼$42.21$3.47B0.08945,305 shs1.09 million shsORICOric Pharmaceuticals$12.10+11.1%$9.39$7.23▼$14.93$1.25B1.021.57 million shs3.61 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%-2.97%+4.72%+13.11%+6.75%DNLIDenali Therapeutics0.00%-0.77%-6.55%+16.31%+59.71%NAMSNewAmsterdam Pharma0.00%-6.44%-6.59%-0.27%+23.60%ORICOric Pharmaceuticals0.00%+12.77%+27.91%+18.16%+2.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.67Moderate Buy$33.1733.52% UpsideDNLIDenali Therapeutics 2.82Moderate Buy$35.1752.17% UpsideNAMSNewAmsterdam Pharma 2.93Moderate Buy$49.4266.72% UpsideORICOric Pharmaceuticals 2.75Moderate Buy$19.2759.28% UpsideCurrent Analyst Ratings BreakdownLatest ORIC, ACAD, NAMS, and DNLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$35.00 ➝ $36.007/21/2026ACADACADIA Pharmaceuticals BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $36.007/21/2026ACADACADIA Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$24.00 ➝ $25.007/20/2026NAMSNewAmsterdam Pharma BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$58.007/20/2026NAMSNewAmsterdam Pharma Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.007/20/2026NAMSNewAmsterdam Pharma BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/17/2026DNLIDenali Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026NAMSNewAmsterdam Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026ORICOric Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/16/2026DNLIDenali Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $35.007/13/2026DNLIDenali Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$26.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B3.97$0.89 per share28.00$7.25 per share3.43DNLIDenali Therapeutics$330.53M11.10N/AN/A$6.91 per share3.34NAMSNewAmsterdam Pharma$22.50M154.00N/AN/A$5.97 per share4.96ORICOric PharmaceuticalsN/AN/AN/AN/A$3.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.2011.2925.8817.2234.30%9.61%7.07%8/4/2026 (Confirmed)DNLIDenali Therapeutics-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)NAMSNewAmsterdam Pharma-$203.82M-$1.79N/AN/AN/A-943.23%-26.49%-24.37%8/5/2026 (Estimated)ORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%8/11/2026 (Estimated)Latest ORIC, ACAD, NAMS, and DNLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ORICOric Pharmaceuticals-$0.36N/AN/AN/AN/AN/A8/10/2026Q2 2026DNLIDenali Therapeutics-$0.5371N/AN/AN/A$2.15 millionN/A8/5/2026Q2 2026NAMSNewAmsterdam Pharma-$0.48N/AN/AN/A$1.88 millionN/A8/4/2026Q2 2026ACADACADIA Pharmaceuticals$0.06N/AN/AN/A$295.51 millionN/A5/7/2026Q1 2026DNLIDenali Therapeutics-$0.73-$0.69+$0.04-$0.69$2.57 millionN/A5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.46-$0.40+$0.06-$0.40$1.75 million$3.04 million5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 million5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48DNLIDenali Therapeutics0.019.289.28NAMSNewAmsterdam PharmaN/A9.769.76ORICOric PharmaceuticalsN/A16.3316.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%DNLIDenali Therapeutics92.92%NAMSNewAmsterdam Pharma89.89%ORICOric Pharmaceuticals95.05%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%DNLIDenali Therapeutics9.70%NAMSNewAmsterdam Pharma12.74%ORICOric Pharmaceuticals5.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableDNLIDenali Therapeutics430158.71 million143.32 millionOptionableNAMSNewAmsterdam Pharma4116.90 million102.01 millionOptionableORICOric Pharmaceuticals80103.52 million97.62 millionOptionableORIC, ACAD, NAMS, and DNLI HeadlinesRecent News About These CompaniesWall Street Zen Upgrades Oric Pharmaceuticals (NASDAQ:ORIC) to SellJuly 25 at 1:37 AM | americanbankingnews.comOric Pharmaceuticals (NASDAQ:ORIC) Upgraded at Wall Street ZenJuly 25 at 1:35 AM | marketbeat.comOric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 5.4% - Time to Buy?July 24 at 12:59 PM | marketbeat.comSiren L.L.C. Has $37.99 Million Holdings in Oric Pharmaceuticals, Inc. $ORICJuly 24 at 6:25 AM | marketbeat.comORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull CaseJuly 21, 2026 | seekingalpha.comORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026July 20, 2026 | globenewswire.comORIC Pharmaceuticals Inc 4TZJuly 16, 2026 | morningstar.comMOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Moderate Buy" by AnalystsJuly 16, 2026 | americanbankingnews.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 16, 2026 | marketbeat.comOric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 6.5% - Here's What HappenedJuly 15, 2026 | marketbeat.comORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical ...July 15, 2026 | markets.businessinsider.comORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with BayerJuly 14, 2026 | globenewswire.comCandriam S.C.A. Buys Shares of 574,085 Oric Pharmaceuticals, Inc. $ORICJuly 13, 2026 | marketbeat.comY Intercept Hong Kong Ltd Sells 229,431 Shares of Oric Pharmaceuticals, Inc. $ORICJuly 11, 2026 | marketbeat.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | globenewswire.comORIC gains as Stifel resumes at buy on upcoming Pfizer readoutJune 13, 2026 | msn.comORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.comORIC Pharmaceuticals Inc ORICMay 31, 2026 | morningstar.comMORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 27, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICMay 21, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026AirJoule Unveils Prime System, Clearing Path to CommercializationBy Thomas Hughes | July 1, 2026PepsiCo’s Dividend Could Turn Patience Into Real ProfitBy Thomas Hughes | July 10, 2026ORIC, ACAD, NAMS, and DNLI Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$24.84 +0.01 (+0.04%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$24.84 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Denali Therapeutics NASDAQ:DNLI$23.11 -0.31 (-1.32%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$23.16 +0.05 (+0.22%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.NewAmsterdam Pharma NASDAQ:NAMS$29.64 -0.91 (-2.98%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$29.63 -0.01 (-0.03%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Oric Pharmaceuticals NASDAQ:ORIC$12.10 +1.21 (+11.11%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$12.14 +0.04 (+0.29%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
